Amy Emerson was most recently chief executive officer (CEO) of Lykos Therapeutics, previously MAPS Public Benefit Corporation, a clinical-stage company dedicated to changing the way mental health conditions are treated. Her leadership of the organization, which formed in 2014, brought focus on medical research and development of psychedelics, starting with MDMA-assisted therapy for those with post-traumatic stress disorder. Amy has decades of pharmaceutical development and research experience and has brought products from Phase 1 studies through FDA approval. From 1993 to 2009, she worked in various fields including immunology, oncology, and vaccines in roles with increasing levels of responsibility for companies such as Novartis and Chiron. Pursuing her love of science and nature, cultivated while growing up in Alaska, Amy earned her B.S. in genetics and cell biology from Washington State University in 1992.